Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Тубулоинтерстициальные болезни почек

Список литературы

  1. Михайлова З., Михайлова Ю. Подагрическая нефропатия: диагностика, подходы к лечению. Врач. 2018; № 7: с.26-29.
  2. Chang J.F., Peng Y.S., Tsai C.C. et al. A possible rare cause of renal failure in streptococcal infection. Nephrol Dial Transplant. 2011; № 1 (26): р. 368-371.
  3. Brewster U.C., Perazella M.A. Proton pump inhibitors and the kidney: critical review. Clin Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int. Suppl. 2012; № 2: р. 1- 126.
  4. Krishnan N., Perazella M.A. Drug-induced acute interstitial nephritis: pathology, pathogenesis, and treatment. Iran J Kidney Dis. 2015; № 1 (9): р. 3-13.
  5. Niemczyk L., Jędras M. Acute tubule-interstitial nephritis. Wiad Lek. 2016; № 5 (69): р. 714-716.
  6. Ruebner R.L., Fadrowski J.J. Tubulointerstitial Nephritis. Pediatr Clin North Am. 2019; № 1 (66): р. 111-119.
  7. Дударева Л.А., Батюшин М.М. Хронический тубулоинтерстициальный нефрит, индуцированный приемом нестероидных противовоспалительных препаратов: эпидемиологические особенности и возможности ранней диагностики. Нефрология. 2013; № 5: – с. 22-26.
  8. Шишкин А.Н. Влияние ятрогении и лекарственной зависимости на поражение внутренних органов. Здоровье – основа человеческого потенциала: проблемы и пути их решения. 2016; № 2: с. 667-670.
  9. Bomback A.S., Markowitz G.S. Increased prevalence of acute interstitial nephritis: more disease or simply more detection? Nephrol Dial Transplant. 2013; № 1 (28): р.16-18.
  10. Blatt A.E., Liebman S.E. Drug-induced acute kidney injury. Hosp. Med. Clin. 2013; № 4 (2): р. 525-541.
  11. Swan S.K., Rudy D.W., Lasseter K.C. et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet: a randomized, controlled trial. Ann Intern Med. 2000; № 1 (133): р. 1-9.
  12. Moledina D.G., Perazella M.A. Treatment of Drug-Induced Acute Tubulointerstitial Nephritis: The Search for Better Evidence. Clin J Am Soc Nephrol. 2018; № 12 (13): р. 1785-1787.
  13. Rossat J., Maillard M., Nussberger J. et al. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther. 1999; № 1 (66): р. 76-84.
  14. Griffin M.R., Yared A., Ray W.A. Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons Am J Epidemiol. 2000; № 5 (151): р. 488-496.
  15. Perez Gutthann S., Garcia Rodriguez L.A., Raiford D.S. et al. Nonsteroidal anti- inflammatory drugs and the risk of hospitalization for acute renal failure. Arch Intern Med. 1996; № 21 (156): р. 2433-2439.
  16. Perazella M.A. Drug use and nephrotoxicity in the intensive care unit. Kidney Int. 2012; № 12 (81): р. 1172-1178.
  17. Praga M., Sevillano A., Auñón P., González E. Changes in the aetiology, clinical presentation and management of acute interstitial nephritis, an increasingly common cause of acute kidney injury. Nephrol Dial Transplant. 2015; № 9 (30): р. 1472-1479.
  18. Jadot I., Declèves A.E., Nortier J., Caron N. An Integrated View of Aristolochic Acid Nephropathy: Update of the Literature. Int J Mol Sci. 2017; № 2 (18): р. 297.
  19. World Health Organization. Some Traditional Herbal Medicines, Some Mycotoxins, Naphthalene and Styrene. In IARC Monographs on the Evaluation of Carcinogenic Risks to Humans; IARC Press: Lyon, France, 2002; № 82: р. 601.
  20. Nortier, J.L., Pozdzik, A., Roumeguere, T., Vanherweghem, J.-L. Néphropathie aux acides aristolochiques (“Néphropathie aux herbes chinoises”). Néphrol. Thér. 2015; № 11: р. 574-588.
  21. Han J., Xian Z., Zhang Y. Systematic Overview of Aristolochic Acids: Nephrotoxicity, Carcinogenicity, and Underlying Mechanisms. Front Pharmacol. 2019; № 10: р. 648.
  22. Jelaković B., Nikolić J., Radovanović Z. et al. Consensus statement on screening, diagnosis, classification and treatment of endemic (Balkan) nephropathy. Nephrol Dial Transplant. 2014; № 29(11): р. 2020-2027.
  23. Jelaković B., Karanović S., Vuković-Lela I. et al. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. Kidney Int. 2012; Vol. 81: р. 559- 567.
  24. EFSA 2006. European Food Safety Authority. Opinion of the Scientific Panel on contaminants in the Food Chain of the EFSA on a request from the Commission related to ochratoxin A in food. EFSA J. 2006; Vol. 365: р. 1-56.
  25. Hodgkins K.S., Schnaper H.W. Tubulointerstitial injury and the progression of chronic kidney disease. Pediatr Nephrol. 2012; № 6 (27): р. 901-909.
  26. Mann S., Seidman M.A., Barbour S.J. et al. Recognizing IgG4- related tubulointerstitial nephritis. Can J Kidney Health Dis. 2016; № 3 (17): р. 34.
  27. Clive D.M., Vanguri V.K. The Syndrome of Tubulointerstitial Nephritis With Uveitis (TINU). Am J Kidney Dis. 2018; № 1 (72): р. 118-128.
  28. Mahévas M., Lescure F.X., Boffa J.J. et al. Renal sarcoidosis: clinical, laboratory, and histologic presentation and outcome in 47 patients. Medicine 2009; Vol. 88: р. 98-106.
  29. Berliner A.R., Haas M., Choi M.J. Sarcoidosis: the nephrologist’s perspective. Am J Kidney Dis 2006; Vol. 48: р. 856-870.
  30. Çaliskan S., Özsoy E., Kaba S. et al. Xanthogranulomatous Pyelonephritis. Arch Iran Med. 2016; № 10 (19): р. 712-714.
  31. Eckardt K.U., Alper S.L., Antignac C. et al. Autosomal dominant tubulointerstitial kidney disease: diagnosis, classification, and management – A KDIGO consensus report. Kidney Int. 2015; № 4 (88): р. 676-683.
  32. Ayasreh N., Miquel R., Matamala A. et al. A review on autosomal dominant tubulointerstitial kidney disease. Nephrologia. 2017; № 3 (37): р. 229-356.
  33. Nast C.C. Medication-Induced Interstitial Nephritis in the 21st Century. Adv Chronic Kidney Dis. 2017; № 2 (24): р. 72-79.
  34. Cerda J., Lameire N., Eggers P. et al. Epidemiology of acute kidney injury. Clin. J. Am. Soc. Nephrol. 2008; № 3 (3): р. 881-886.
  35. Goicoechea M, Rivera F, Lopez-Gomez JM. Spanish registry of glomerulonephritis. NDT. 2013; № 28(1): р. 112-115.
  36. Joyce E., Glasner P., Ranganathan S., Swiatecka-Urban A. Tubulointerstitial Nephritis: Diagnosis, Treatment and Monitoring. Pediatr Nephrol. 2017; № 4 (32): р. 577-587.
  37. Wheeler E., Thomas S. Diagnosis and Long-term Management of Uromodulin Kidney Disease. Cureus. 2019; № 3 (11): р. 4270.
  38. Bleyer A.J., Kidd K., Zivna M., Kmoch S. Autosomal dominant Tubulointerstitial kidney disease. Adv Chronic Kidney Dis. 2017; Vol. 24: р. 86-93.
  39. Lhotta K., Piret S.E., Kramar R. et al. Epidemiology of uromodulin-associated kidney disease – results from a nation-wide survey. Nephron Extra. 2012; Vol. 2: р. 147-158.
  40. Raffler G., Zitt E., Sprenger-Ma¨hr H. et al. Autosomal dominant tubulointerstitial kidney disease caused by uromodulin mutations: seek and you will find. Wien Klin Wochenschr 2016; Vol. 128: р. 291-294.
  41. Helms E., Servilla K.S., Hartshorne M.F. et al. Tubulointerstitial nephritis and uveitis syndrome: use of gallium scintigraphy in its diagnosis and treatment. In t Urol Nephrol. 2005; Vol. 37: р. 119-122.
  42. Weinstein O., Tovbin D., Rogachev B. et al. Clinical manifestations of adult tubulointerstitial nephritis and uveitis (TINU) syndrome. Int Ophthalmol. 2010; Vol. 30: р. 621- 628.
  43. Carvalho T.J., Calça R., Cassis J., Mendes A. Tubulointerstitial nephritis and uveitis syndrome in a female adult. BMJ Case Rep. 2019; № 1 (12): р. 227688.
  44. Mackensen F., Smith J.R., Rosenbaum J.T. Enhanced recognition, treatment, and prognosis of tubulointerstitial nephritis and uveitis syndrome. Ophthalmology. 2007; № 5 (114): р. 995-999.
  45. Kobayashi Y., Honda M., Yoshikawa N., Ito H. Acute tubulointerstitial nephritis in 21 Japanese children. Clin Nephrol. 2000; № 3 (54): р. 191-197.
  46. Karras A. Acute interstitial nephritis. Rev Prat. 2018; № 2 (68): р. 170-174.
  47. Ramachandran R., Kumar K., Nada R. et al. Drug-induced acute interstitial nephritis: A clinicopathological study and comparative trial of steroid regimens. Indian J Nephrol. 2015; № 5 (25): р. 281-286.
  48. Bollee G., Dahan K., Flamant M. et al. Phenotype and outcome in hereditary tubulointerstitial nephritis secondary to UMOD mutations. Clin J Am Soc Nephrol. 2011; Vol. 6: р. 2429-2438
  49. Gokmen M, Cosyns J, Arlt V.M. et al. The Epidemiology, Diagnosis, and Management of Aristolochic Acid Nephropathy. Ann. Intern. Med. 2013; Vol. 158: р. 469-477
  50. Bonkat G., Bartoletti R.R., Bruyere F. et al. Urological Infections. Guidelines of European Association of Urology. 2019. URL: htpp: // uroweb.org/guideline/urological- infections/#note_159.
  51. Chapagain A., Dobbie H., Sheaff M. et al. Presentation, diagnosis, and treatment outcome of tuberculous-mediated tubulointerstitial nephritis. Kidney Int 2011; Vol. 79: р. 671- 677.
  52. Eastwood J.B., Corbishley C.M., Grange J.M. Tuberculosis and tubulointerstitial nephritis: an intriguing puzzle. Kidney Int. 2011; Vol. 79: р. 579-581.
  53. Goules A., Geetha D., Arend L.J., Baer A.N. Renal involvement in primary Sjögren's syndrome: natural history and treatment outcome. Clin Exp Rheumatol. 2019;37 Suppl 118(3):123-132.
  54. Koeze J., Keus F., Dieperink W. et al. Incidence, timing and outcome of AKI in critically ill patients varies with the definition used and the addition of urine output criteria. BMC Nephrol. 2017;18(1):70.
  55. Kelly C.J., Neilson E.G. Tubulointerstitial diseases. In Brenner&Rector’s The Kidney. Ninth Ed. US. Elsevier. 2012. 1332-1356.
  56. Perneger T.V., Whelton P.K., Klag M.J. Risk of Kidney Failure Associated with the Use of Acetaminophen, Aspirin, and Nonsteroidal Antiinflammatory Drugs. N Engl J Med 1994; № 331: р. 1675-1679.
  57. Murray T.G., Stolley P.D., Anthony J.C. et al. Epidemiologic study of regular analgesic use and end-stage renal disease. Arch Intern Med. 1983; № 143(9): р. 1687-1693.
  58. Morlans M., Laporte J.R., Vidal X. et al. End-stage renal disease and non-narcotic analgesics: a case-control study. Br J Clin Pharmacol. 1990; № 30(5): р. 717-723.
  59. Sandler D.P., Burr F.R., Weinberg C.R. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med. 1991; № 115(3): р. 165-172.
  60. Батюшин М.М., Дмитриева О.В., Терентьев В.П., Давиденко К.С. Расчетные методы прогнозирования риска развития анальгетического интерстициального поражения почек. Тер. арх. 2008; № 6: с. 62-65.
  61. Mandeville J.T.H., Levinson R.D., Holland G.N. The tubulointerstitial nephritis and uveitis syndrome. Surv Ophthalmol. 2001; № 3 (46): р. 195-208.
  62. Ronco C., Bellomo R., Kellum J.A., Ricci Z. Critical care nephrology. Third ed. USA. Elsevier. 2019. 1411.
  63. Клинические рекомендации по ХБП, ОПП. Ассоциация нефрологов. Ссылка взята 10.03.2021. https://rusnephrology.org/professional/
  64. Cavanaugh C., Perazella M.A. Urine Sediment Examination in the Diagnosis and Management of Kidney Disease: Core Curriculum 2019. Am J Kidney Dis. 2019; № 73(2): р. 258-272.
  65. Щербак А., Бобкова И.Н., Козловская Л.В. Профилактика и лечение поражения почек у больных с уратным дисметаболизмом. Врач. 2013; №6: с. 6-10.
  66. Meola M., Petrucci I. L'ecografia e il color-Doppler nella malattia renale cronica [Ultrasound and color Doppler applications in chronic kidney disease]. G Ital Nefrol. 2012; № 29(6): р. 699-715.
  67. Perazella M.A. Clinical Approach to Diagnosing Acute and Chronic Tubulointerstitial Disease. Adv Chronic Kidney Dis. 2017; № 24(2): р. 57-63.
  68. Андросова С.О., Фомин В.В., Шилов Е.М. Тубулоинтерстициальный нефрит. Гл.32 в кн. Нефрология. Нац. Рук. М.: Гэотар-Медиа. 2009. С. 403-412.
  69. Praga M., Sevillano A., Auñón P., González E. Changes in the aetiology, clinical presentation and management of acute interstitial nephritis, an increasingly common cause of acute kidney injury. Nephrol Dial Transplant. 2015; № 9 (30): р. 1472-1479.
  70. Leven C., Hudier L., Picard S. et al. Prospective study of drug-induced interstitial nephritis in eleven French nephrology units. Presse Med. 2014; № 11 (43): р. 369-376.
  71. Perazella M.A., Markowitz G.S. Drug-induced acute interstitial nephritis. Nat. Rev. Nephrol. 2010; Vol. 6: р. 461-470.
  72. Pannu N., Nadim M.K. An overview of drug-induced acute kidney injury. Crit. Care Med. 2008; № 4 (36): р. 216-223.
  73. Prowle J.R., Echeverri J.E., Ligabo E.V. et al. Fluid balance and acute kidney injury. Nat. Rev. Nephrol. 2010; Vol. 6: р. 107-115.
  74. Wang A.Y., Bellomo R., Ninomiya T. et al. RENAL Study Investigators; ANZICS Clinical Trials Group. Angiotensin-converting enzyme inhibitor usage and acute kidney injury: a secondary analysis of RENAL study outcomes. Nephrology (Carlton). 2014; № 19(10): р. 617- 622.
  75. Ravioli S., Pluess E., Funk G.C. et al. Dyskalemias in patients with acute kidney injury presenting to the emergency department are common and independent predictors of adverse outcome. Int J Clin Pract. 2021; № 75(1): р. 13653.
  76. Sprenger-Mahr H., Zitt E., Lhotta K. Acute kidney injury treated with dialysis outside the intensive care unit: a retrospective observational single-center study. PLoS ONE. 2016; № 11: р.0163512.
  77. Li L., Yang C., Zhao Y. et al. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: A systematic review and meta-analysis based on observational cohort studies. BMC Nephrol. 2014; Vol. 15: р. 122.
  78. Stack A.G., Johnson M.E., Blak B. et al. Gout and the risk of advanced chronic kidney disease in the UK health system: a national cohort study. BMJ Open. 2019; № 8 (9): р. 031550.
  79. Kim W.J., Song J.S., Choi S.T. et al. The Role of a "Treat-to-Target" Approach in the Long-Term Renal Outcomes of Patients with Gout. J Clin Med. 2019; № 7 (8): р. 1067.
  80. Bose B., Badve S.V., Hiremath S.S. et al. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2014; № 2 (29): р. 406-413.
  81. Kanji T., Gandhi M., Clase C.M., Yang R. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 2015; Vol. 16: р. 58.
  82. Kim S.H., Lee S.Y., Kim J.M., Son C.N. Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis. Korean J Intern Med. 2019. doi: 10.3904/kjim.2018.423.
  83. Lee J.W., Lee K.H. Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease. Int Urol Nephrol. 2019; Vol. № 3 (51): р. 467-473.
  84. Liu X., Wang H., Ma R. et al. he urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5. Clin Exp Nephrol. 2019; № 3 (23): р. 362-370.
  85. Yu H., Liu X., Song Y. et al. Safety and Efficacy of Benzbromarone and Febuxostat in Hyperuricemia Patients with Chronic Kidney Disease: A Prospective Pilot Study. Clin Exp Nephrol. 2018; № 6 (22): р. 1324-1330.
  86. Chou H.W., Chiu H.T., Tsai C.W. et al. Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study. Nephrol Dial Transplant. 2018; № 9 (33): р. 1620-1627.
  87. Kim W.J., Kim S.H.,, Chung TT, Yu KH, Kuo CF, Luo SF, Chiou MJ, Lan WC, Chen JS, Tseng WY, Hsieh AH, Wang LC. Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients. Arthritis Res Ther. 2019; №21(1): р.210.
  88. Lin T.C., Hung L.Y., Chen Y.C. et al. Effects of febuxostat on renal function in patients with chronic kidney disease: A systematic review and meta-analysis. Medicine (Baltimore). 2019; №98(29): р. 16311.
  89. González E., Gutiérrez E., Galeano C. et al. Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int. 2008; №73(8): р.940-946.
  90. Fernandez-Juarez G., Perez J.V., Caravaca-Fontán F. et al. Duration of Treatment with Corticosteroids and Recovery of Kidney Function in Acute Interstitial Nephritis. Clin J Am Soc Nephrol. 2018; №13(12): р.1851-1858.
  91. Surendra M., Raju S., Chandragiri S. et al. Steroid therapy in drug induced acute interstitial nephritis - Retrospective analysis of 83 cases. Saudi J Kidney Dis Transpl. 2019; № 1 (30): р. 157-165.
  92. Clarkson M.R., Giblin L., O’Connell F.P. et al. Acute interstitial nephritis: clinical features and response to corticosteroid therapy. Nephrol Dial Transplant 2004; Vol. 19: р. 2778- 2783.
  93. Chowdry A.M., Azad H., Mir I. et al. Drug-induced acute interstitial nephritis: Prospective randomized trial comparing oral steroids and high-dose intravenous pulse steroid therapy in guiding the treatment of this condition. Saudi J Kidney Dis Transpl. 2018; № 3 (29): р. 598-607.
  94. Hausler U., Guminski B., Helmchen U. et al. Tubulointerstitial nephritis with uveitis (TINU) syndrome. A relatively rare rheumatological differential diagnosis with unexplained uveitis. Z Rheumatol. 2013; № 4 (72): р. 393-397.
  95. Buscher R., Vij O., Hudde T. et al. Pseudotumor cerebri following cyclosporine A treatment in a boy with tubulointerstitial nephritis associated with uveitis. Pediatr Nephrol. 2004; № 5 (19): р. 558-560.
  96. Sobolewska B., Bayyoud T., Deuter C. et al. Long-term Follow-up of Patients with Tubulointerstitial Nephritis and Uveitis (TINU) Syndrome. Ocul Immunol Inflamm. 2018; №26(4): р. 601-607.
  97. Mackensen F., Smith J.R., Rosenbaum J.T. Enhanced recognition, treatment, and prognosis of tubulointerstitial nephritis and uveitis syndrome. Ophthalmology. 2007; №114(5): р.995-999.
  98. Клинический рекомендации. Артериальная гипертензия у взрослых. Ссылка взята 09.04.2021 https://scardio.ru/content/Guidelines/Clinic_rek_AG_2020.pdf
  99. Lufft V., Kliem V., Hamkens A. et al. Antiproteinuric efficacy of fosinopril after renal transplantation is determined by the extent of vascular and tubulointerstitial damage. Clin Transplant. 1998; Vol. 12: р. 409-415.
  100. Haas M., Leko-Mohr Z., Erler C., Mayer. G. Antiproteinuric versus antihypertensive effects of high-dose ACE inhibitor therapy. Am J Kidney Dis. 2002; Vol. 40: р. 458-463.
  101. Laverman G.D., Henning R.H., de Jong P.E. et al. Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria. Am J Kidney Dis. 2001; Vol. 38: р. 1381-1384.
  102. Agodoa L.Y., Appel L., et al. for the African American Study of Kidney Disease and Hypertension (AASK) Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. JAMA. 2001; Vol. 285: р. 2719-2728.
  103. Jafar T.H., Schmid C.H., Landa M., et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med. 2001; № 2 (135): р. 73-87.
  104. Heerspink H.J.L., Stefánsson B.V., Correa-Rotter R. et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-1446.
  105. Федеральные клинические рекомендации по диагностике и лечению болезни Шегрена. Ассоциация ревматологов России – взято с сайта 12.04.2021. http://www.ma.cfuv.ru/docs/249615/%D0%91%D0%BE%D0%BB%D0%B5%D0%B7%D0%B D%D1%8C%20%D0%A8%D0%B5%D0%B3%D1%80%D0%B5%D0%BD%D0%B0.pdf
  106. Рекомендации по лечению системных васкулитов – Ассоциация ревматологов России . взято с сайта 12.04.2021. https://rheumatolog.ru/system/files/pdf/nacrec/natrec24.pdf
  107. Клинические рекомендации. Системная красная волчанка. Ассоциация ревматологов России – взято с сайта 12.04.2021. http://kokb45.ru/wp- content/uploads/2018/06/Sistemnaya-krasnaya-volchanka.pdf
  108. Hilderson I., Van Laecke S., Wauters A. et al. Treatment of renal sarcoidosis: is there a guideline? Overview of the different treatment options. Nephrol Dial Transplant. 2014; Vol. 29: р. 1841-1847.
  109. Moudgil A., Prygodzki R.M., Kher K.K. Successful steroid-sparing treatment of renal limited sarcoidosis with mycophenolate mofetil. Pediatr Nephrol. 2006; Vol. 21: р. 281- 285.
  110. Ungprasert P., Cheungpasitporn W., Crowson C.S., Matteson E.L. Individual non- steroidal anti-inflammatory drugs and risk of acute kidney injury: A systematic review and meta-analysis of observational studies. Eur J Intern Med. 2015; №26(4): р.285-291.
  111. Zhang X., Donnan P.T., Bell S., Guthrie B. Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 2017; №18(1): р.256.

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*